Active substance
Sucralfate
- SFDA 4
- US FDA 16
- Health Canada 4
- US price lines 5
- NHS prices 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| GASTROFAIT TAB 500MG | 500 mg | Tablet · Oral use | 20 Blister | SAR 11.80 | NCE · Prescription | EIPICO | Valid |
| ULCICURE TAB 1 GM | 1 g | Tablet · Oral use | 30 Blister | SAR 11.25 | Generic · Prescription | ALAMRIAH FOR PHARMACEUTICALS INDUSTRIES | Withdrawn by MAH · Not Marketed |
| ULSAHEAL 1000 SUSP (1000MG-5ML) | 200 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 26.50 | NCE · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| ULSAHEAL TAB 1G | 1 g | Tablet · Oral use | 50 Blister | SAR 20.80 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
DYSPEPSIA; GASTROESOPHAGEAL REFLUX DISEASE (GERD)
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CARAFATE | 1GM | tablet · oral | ABBVIE | Prescription | 30 Oct 1981 |
| SUCRALFATE | 1GM | tablet · oral | TEVA | Prescription | 29 Mar 1996 |
| SUCRALFATE | 1GM | tablet · oral | CHARTWELL RX | Prescription | 8 Jun 1998 |
| SUCRALFATE | 1GM/10ML | suspension · oral | AMNEAL | Prescription | 2 Dec 2019 |
| SUCRALFATE | 1GM/10ML | suspension · oral | VISTAPHARM LLC | Prescription | 15 Mar 2022 |
| SUCRALFATE | 1GM | tablet · oral | AMNEAL PHARMS | Prescription | 15 Apr 2022 |
| SUCRALFATE | 1GM/10ML | suspension · oral | MYLAN | Prescription | 12 Sep 2022 |
| SUCRALFATE | 1GM | tablet · oral | ZYDUS LIFESCIENCES | Prescription | 3 May 2023 |
| SUCRALFATE | 1GM/10ML | suspension · oral | PD PARTNERS | Prescription | 17 Jan 2024 |
| SUCRALFATE | 1GM/10ML | suspension · oral | ABON PHARMS LLC | Prescription | 21 Mar 2024 |
| SUCRALFATE | 1GM/10ML | suspension · oral | STRIDES PHARMA | Prescription | 21 May 2024 |
| SUCRALFATE | 1GM/10ML | suspension · oral | COSETTE PHARMS NC | Prescription | 13 Nov 2024 |
| SUCRALFATE | 1GM/10ML | suspension · oral | CHARTWELL RX | Prescription | 14 Apr 2025 |
| SUCRALFATE | 1GM/10ML | suspension · oral | GLENMARK PHARMS LTD | Prescription | 5 Jan 2026 |
| CARAFATE | 1GM/10ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | suspension · oral | ABBVIE | Discontinued | 16 Dec 1993 |
| SUCRALFATE | 1GM/10ML | suspension · oral | HIKMA PHARMS | Discontinued | 23 Jul 2024 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AA-SUCRALFATE | 02125250 | 1 G | TABLET · ORAL | AA PHARMA INC |
| SULCRATE | 02100622 | 1 G | TABLET · ORAL | ABBVIE CORPORATION |
| SULCRATE SUSPENSION PLUS | 02103567 | 1 G / 5 ML | SUSPENSION · ORAL | ABBVIE CORPORATION |
| TEVA-SUCRALFATE | 02045702 | 1 G | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CARAFATE 1 GM TABLET | $4.73077 | per EA | 23 Sep 2026 |
| US NADAC | SUCRALFATE 1 GM TABLET | $0.1727 | per EA | 23 Sep 2026 |
| US NADAC | SUCRALFATE 1 GM/10 ML SUSP | $0.12412 | per ML | 23 Sep 2026 |
| US NADAC | SUCRALFATE 1 GM/10 ML SUSP | $0.13714 | per ML | 23 Sep 2026 |
| US NADAC | SUCRALFATE 1 GM/10 ML SUSP | $0.11631 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Sucralfate 1g/5ml oral suspension sugar free | £288.48 | 200 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 15 Aug 2017 CARAFATE — safety-related labeling change
Labeling sections changed: Warnings and Precautions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.